<DOC>
	<DOCNO>NCT00337194</DOCNO>
	<brief_summary>This randomized phase II trial study side effect well give monoclonal antibody SGN-30 together combination chemotherapy work treat patient Hodgkin lymphoma return period improvement respond previous treatment . Monoclonal antibody , SGN-30 , may interfere ability cancer cell grow spread . Drugs use chemotherapy , gemcitabine hydrochloride , vinorelbine tartrate , pegylated liposomal doxorubicin hydrochloride , work different way stop growth cancer cell , either kill cell stop divide . Giving monoclonal antibody SGN-30 together combination chemotherapy may kill cancer cell shrink tumor .</brief_summary>
	<brief_title>SGN-30 Combination Chemotherapy Treating Patients With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete partial response rate follow treatment anti-cluster differentiation ( CD ) 30 antibody , SGN-30 ( monoclonal antibody SGN-30 ) , gemcitabine ( gemcitabine hydrochloride ) , vinorelbine ( vinorelbine tartrate ) , pegylated liposomal doxorubicin ( pegylated liposomal doxorubicin hydrochloride ) ( GVD ) patient relapse refractory Hodgkin lymphoma ( HL ) . II . To assess time progression overall survival patient treat SGN-30 GVD patient relapse refractory Hodgkin lymphoma ( HL ) . III . To evaluate toxicity SGN-30 combination GVD patient relapse refractory HL . SECONDARY OBJECTIVES : I . To determine pharmacokinetic profile SGN-30 combine GVD chemotherapy . II . To correlate soluble ( ) CD30 level response treatment . III . To determine incidence human anti-chimeric antibody ( HACA ) formation follow repetitive SGN-30 dosing . IV . To correlate Fc gamma receptor polymorphisms response treatment . OUTLINE : Part 1 ( close accrual 5/18/2007 ) : Patients receive monoclonal antibody SGN-30 intravenously ( IV ) 2 hour , vinorelbine tartrate IV 6-10 minute , gemcitabine hydrochloride IV 30 minute , pegylated doxorubicin hydrochloride liposome IV 90 minute day 1 8 . Treatment repeat every 21 day 10 16 patient complete 1 course absence unacceptable toxicity . Subsequent patient receive treatment part 2 . Part 2 : Patients randomize 1 2 treatment arm . Arm I : Patients receive monoclonal antibody SGN-30 IV 2 hour , vinorelbine tartrate IV 6-10 minute , gemcitabine hydrochloride IV 30 minute , pegylated doxorubicin hydrochloride liposome IV 90 minute day 1 8 . Arm II ( close accrual 12/4/07 ) : Patients receive placebo IV 2 hour , vinorelbine tartrate IV 6-10 minute , gemcitabine hydrochloride IV 30 minute , pegylated doxorubicin hydrochloride liposome IV 90 minute day 1 8 . Treatment arm repeat every 21 day 6 course absence disease progression unacceptable toxicity . NOTE : Treatment SGN-30/placebo stop 4/12/2007 due pulmonary toxicity . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically document CD30positive classical Hodgkin lymphoma accord World Health Organization ( WHO ) classification lymphoid malignancy recurrent refractory least one prior therapy Note : Patients nodular lymphocyte predominant HL eligible ; subtypes include nodular sclerosis , lymphocytedepleted , lymphocyte rich , mixed cellularity HL may enrol Core needle biopsy acceptable contain adequate tissue primary diagnosis immunophenotyping ; bone marrow biopsy sole mean diagnosis acceptable , may submit conjunction nodal biopsy ; fine needle aspirate acceptable ; original diagnostic specimen available , specimen obtain relapse may submit ; multiple specimen available , please submit recent ; failure submit pathology specimen within 60 day patient registration consider major protocol violation Patients must relapse refractory disease least one prior therapy , least 3 week interval completion recent chemotherapy radiotherapy regimen ; recovery = &lt; grade 1 toxicity relate prior treatment require ; patient previously receive stem cell transplant permit enroll study Prior treatment antiCD30 antibody , gemcitabine , vinorelbine , pegylated liposomal doxorubicin permit No uncontrolled angina , myocardial infarction ( MI ) within 6 month study entry , New York Heart Association ( NYHA ) class II great congestive heart failure ( CHF ) Baseline leave ventricular ejection fraction ( LVEF ) multi gate acquisition scan ( MUGA ) echocardiogram ( ECHO ) must &gt; = 45 % Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Measurable disease must present either physical examination image study ; evaluable nonmeasurable disease alone acceptable Measurable disease define lesion accurately measure least one dimension ( long diameter record ) &gt; = 10 mm Nonmeasurable disease include lesion , include small lesion ( &lt; 10 mm ) truly nonmeasurable lesion Lesions consider nonmeasurable include follow : Bone lesion ( lesion , present , note ) Bone marrow involvement ( present , note ) Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Pregnant nursing woman may enrol ; woman childbearing potential must negative serum urine pregnancy test prior registration ; woman men reproductive potential agree use effective mean birth control Corrected diffusion capacity carbon monoxide ( DLCO ) &gt; = 50 % Absolute neutrophil count ( ANC ) &gt; = 1,200/uL Platelet count &gt; = 100,000/uL Creatinine = &lt; 2.0 mg/dL Bilirubin = &lt; 2.0 mg/dL Absent history Gilbert 's disease Aspartate aminotransferase ( AST ) = &lt; 2.0 x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>